<DOC>
	<DOCNO>NCT00083759</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability efficacy natalizumab subject diagnose moderate severe rheumatoid arthritis ( RA ) receive concomitant treatment methotrexate ( MTX ) . It think natalizumab may stop movement certain white blood cell , know lymphocyte , joint tissue . These cell think cause damage joint lead symptom RA .</brief_summary>
	<brief_title>Natalizumab Treatment Rheumatoid Arthritis Subjects Receiving Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Subjects eligible begin study participation meet follow inclusion criterion : Subject able read , understand , voluntarily sign approve Informed Consent form prior performance studyspecific procedure ; Male female subject , ≥18 ≤75 year age , diagnosis rheumatoid arthritis Functional Class 1 3 1987 Revised American Rheumatism Association Criteria Classification Rheumatoid Arthritis least 6 month prior screen ; Subject stable dose MTX least 10 mg/week ≥3 month prior randomization ( Month 0 ) without adequate response ; Female subject childbearing potential agree use adequate , contraceptive method ( either intrauterine device [ IUD ] , oral depot contraceptive , barrier plus spermicide ) . Female subject childbearing potential use adequate contraception least 2 month prior study entry continue contraception least 3 month last infusion study drug ; Subject willing able complete plan study procedure ; Subject least 10 painful/tender 6 swollen joint Month 0 ( Baseline ) visit ; Subject elevate CRP level ( define &gt; 2.87 mg/L ) Screening . Subjects exclude study meet follow exclusion criterion : Subject pregnant lactating ; Subject experience inadequate therapeutic response least 3 month treatment least one TNFalpha inhibitor ; Subject receive treatment anakinra ; Subject receive prior treatment natalizumab ; Subject meet follow criterion regard concomitant medication RA : Use oral steroid exceed 10 mg/day prednisone ( equivalent dose ) administer stable dose least 1 month prior randomization ( Month 0 ) ; Use NSAIDs unless stable least 1 month prior randomization ( Month 0 ) ; Use antiarthritic treatment , include approve experimental oral , topical , injectable biologics drug , device within 1 month prior randomization ( Month 0 ) ; Intraarticular corticosteroid injection within 1 month prior randomization ( Month 0 ) ; Treatment TNFalpha inhibitor within 2 month prior randomization ( Month 0 ) ; Subject expect unavailable duration trial , likely noncompliant Protocol , felt unsuitable Investigator reason ; Subject history malignancy ( basal cell carcinoma skin ) ; Subject history clinically significant and/or persistent gastrointestinal , pulmonary , chronic infection , cardiovascular , renal , hepatic , neurological , dermatological , immunological , major psychiatric ( include drug alcohol abuser ) hematological illness , , opinion Investigator place subject unacceptable risk participation study ; Subject laboratory test Screening consider significantly abnormal . An alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≥1.5 x upper limit normal ( ULN ) cytopenia ( include following : WBC &lt; 3.5 x 1000/uL ; hemoglobin [ Hb ] &lt; 8 g/dL ; platelet &lt; 100 x 1000/uL ; and/or neutrophil absolute &lt; 1.0 x 1000/uL ) consider significantly abnormal ; Subject intend donate blood blood product period study within 1 month follow completion study ; Subject positive tuberculosis ( TB ) skin test Screening within 30 day prior Screening ( define ≥10 mm induration ) ; Subject plan require surgical procedure study treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>